Curtis Craig, MD
Family Medicine · Washington, MINPI 1255392361
Payments from drug & device makers
Across 158 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$707
- Pfizer$275
- Lilly USA, LLC$192
- AstraZeneca$135
- AbbVie$133
- Amgen$128
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,60893%
- Education$1837%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $707 |
| Pfizer | 20 | $275 |
| Lilly USA, LLC | 16 | $192 |
| AstraZeneca | 9 | $135 |
| AbbVie(2 entities) | 3 | $133 |
| Amgen | 8 | $128 |
| Edwards Lifesciences | 1 | $104 |
| Astellas Pharma US Inc | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $87 |
| Exact Sciences | 5 | $82 |
| Currax Pharmaceuticals LLC | 3 | $75 |
| GSK | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Merck | 4 | $49 |
| Medtronic | 1 | $47 |
| Novartis | 3 | $42 |
| Bayer | 2 | $42 |
| Johnson & Johnson | 3 | $41 |
| Boehringer Ingelheim | 3 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $36 |
| Seqirus USA Inc | 2 | $35 |
| Abiomed | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,792 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 356 | $423,490 |
| OzempicSemaglutide | 160 | $216,317 |
| JanuviaSitagliptin Phosphate | 186 | $214,305 |
| MounjaroTirzepatide | 146 | $185,281 |
| JardianceEmpagliflozin | 113 | $148,464 |
| XareltoRivaroxaban | 94 | $126,895 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $68,931 |
| EntrestoSacubitril/Valsartan | 28 | $47,958 |
| MyrbetriqMirabegron | 51 | $47,820 |
| TrulicityDulaglutide | 34 | $46,360 |
| RybelsusSemaglutide | 24 | $40,287 |
| InvokanaCanagliflozin | 17 | $27,606 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $22,913 |
| FarxigaDapagliflozin Propanediol | 16 | $18,988 |
| Mirabegron ErMirabegron | 19 | $16,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $275 | $434,491394 claims |
| Novo NordiskOzempic, Rybelsus | $707 | $256,604184 claims |
| Lilly USA, LLCMounjaro, Trulicity | $192 | $231,641180 claims |
| MerckJanuvia, Dulera | $49 | $225,368208 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $40 | $162,406129 claims |
| Johnson & JohnsonXarelto, Invokana | $41 | $154,501111 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $64 | $91,84594 claims |
| NovartisEntresto | $42 | $47,95828 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $47,82051 claims |
| AstraZenecaFarxiga, Symbicort | $135 | $28,62339 claims |
| AbbVieLinzess | $133 | $12,39611 claims |
| Esperion Therapeutics, Inc.Nexlizet | $37 | $11,68518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Washington
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.